Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

November 11, 2011

Primary Completion Date

March 28, 2023

Study Completion Date

August 2, 2026

Conditions

Advanced Malignant Solid Neoplasm

Interventions

DRUG

Dinaciclib

Given IV

DRUG

Veliparib

Given PO

Trial Locations (2)

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH